Cellectar Biosciences to Present at 27th Annual Roth Conference
04 März 2015 - 2:30PM
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage
biopharmaceutical company developing innovative agents for the
detection and treatment of cancer, today announced that Dr. Jamey
Weichert, Chief Scientific Officer and founder, will present at the
27th Annual Roth Conference on Tuesday, March 10, 2015 at 03:30 pm
PDT at the Ritz Carlton in Laguna Niguel, California.
A live audio webcast of the presentation will be available on
Cellectar's website at www.cellectar.com. A webcast replay will be
available approximately two hours after the presentation ends and
will be archived for 30 days.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing agents to detect, treat and
monitor a broad spectrum of cancers. Using a novel phospholipid
ether (PLE) analog platform technology as a targeted delivery and
retention vehicle, Cellectar's compounds are designed to be
selectively taken up and retained in cancer cells including cancer
stem cells. With the ability to attach both imaging and therapeutic
agents to its proprietary delivery platform, Cellectar has
developed a portfolio of product candidates engineered to leverage
the unique characteristics of cancer cells to "find, treat and
follow" malignancies in a highly selective way. I-124-CLR1404 is a
small-molecule, broad-spectrum, cancer-targeted PET imaging agent
currently being evaluated in a Phase II glioblastoma imaging trial.
Additionally, multiple investigator-sponsored Phase I/II clinical
trials are ongoing across 11 solid tumor indications. I-131-CLR1404
is a small-molecule, broad-spectrum, cancer-targeted molecular
radiotherapeutic that delivers cytotoxic radiation directly and
selectively to cancer cells including cancer stem cells. A Phase Ib
dose-escalation trial of I-131-CLR1404 in patients with advanced
solid tumors was completed in the first quarter of 2014 and results
presented at the American Society of Clinical Oncology (ASCO) 2014
Annual Meeting. CLR1502 is a preclinical, cancer-targeted,
non-radioactive optical imaging agent for intraoperative tumor
margin illumination and non-invasive tumor imaging. For additional
information please visit www.cellectar.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form 10-K
for the year ended December 31, 2013. These forward-looking
statements are made only as of the date hereof, and we disclaim any
obligation to update any such forward-looking statements.
CONTACT: INVESTOR CONTACT
Kate McNeil
Vice President of IR, PR & Corporate Communications
Cellectar Biosciences, Inc.
Phone: (347) 204-4226
Email: kmcneil@cellectar.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024